Skip to main content

Articles

Leukemia, Oncology
Adding Ibrutinib to Standard Therapy Reduces Disease Progression by 80% in Previously Treated Patients with CLL
Read More
Leukemia, Oncology
Adherence to Ibrutinib Therapy Improves Outcomes in Patients with CLL
Read More
Immunotherapy, Oncology
Immunotherapies Steal the Show at ASCO 2015
Read More
Immunotherapy, Oncology
Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma
Read More
Arming Providers and Payers with Treatment- and Value-Based Management Tools for Battling Cancer
Read More
FDA Approvals
Lemtrada (Alemtuzumab) a New Treatment Option Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis
Read More
FDA Approvals
Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma
Read More
Perspectives
The Continuation of Care
Read More
Introduction
Health Economics in Oncology: A Necessary Tool for Value-Based Patient Care
Read More
Practice Management
Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer
Stakeholder Perspective
Comparing Cost and Utilization of 2 Therapies for Metastatic Castration-Resistant Prostate Cancer
Read More
Page 131 of 244
Results 1301 - 1310 of 2436